Table 3.

Responses to questions involving the relevance of cardiac catheterization and pulmonary vasoreactivity testing to the diagnosis/management of pulmonary arterial hypertension

Survey question	Response (N = 105), mean ± SD (range)
A key guideline for determining the timing of invasive hemodynamic assessment for patients with pulmonary arterial hypertension (PAH) in your practice is the expert consensus guideline statement on the topic published in 200912	4.4 ± 2.2 (1–7)
It is reasonable to perform pulmonary vasoreactivity testing as part of the clinical evaluation for patients with suspected chronic lung disease–induced pulmonary hypertension (i.e., World Health Organization [WHO] group 3 pulmonary hypertension)	3.1 ± 2.1 (1–7)
A substantial decrease in pulmonary hypertension severity on pulmonary vasoreactivity testing influences your choice of first-line pulmonary vasodilator therapy in patients requiring treatment of symptomatic PAH	5.6 ± 1.7 (1–7)
Right heart catheterization is a routine strategy by which to monitor (i.e., follow-up) the treatment responsiveness of PAH patients to pulmonary vasodilator therapy	4.1 ± 2.0 (1–7)
Among patients initiated on pulmonary circulation–specific therapy following invasive hemodynamic assessment, a repeat right heart catheterization is performed in your practice in patients with clinical deterioration only	4.3 ± 2.1 (1–7)

^NoteAnswers are reported on the basis of a 7-point Likert scale (1 = disagree, 7 = agree).